ZEGERID (omeprazole, sodium bicarbonate) by Salix Pharmaceuticals is proton pump inhibitors [moa]. Approved for sodium bicarbonate for oral suspension is indicated in adults for: reduction of risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2004.
Drug data last refreshed 14h ago · AI intelligence enriched Yesterday
ZEGERID is an oral suspension combining omeprazole (a proton pump inhibitor) with sodium bicarbonate, approved in 2004 for reducing the risk of upper GI bleeding in critically ill patients. The sodium bicarbonate component enables rapid acid neutralization and faster omeprazole absorption compared to standard formulations. It works by irreversibly inhibiting gastric acid secretion through H+/K+-ATPase inhibition.
With LOE approaching and competitive pressure at 30%, teams supporting ZEGERID face a narrowing commercial window requiring focus on retention and cost management rather than growth expansion.
Proton Pump Inhibitors
Proton Pump Inhibitor
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
Worked on ZEGERID at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ZEGERID represents a specialized, declining asset with minimal career growth opportunity; the single linked role (OSD Technology) suggests focus on manufacturing optimization and cost reduction rather than commercial expansion. Professionals joining this product should expect legacy management responsibilities, process efficiency projects, and eventual transition planning as LOE approaches.
1 open roles linked to this drug